NICHOLAS J DAWSON FUGATE

Allopathic & Osteopathic Physicians|Family Medicine PINEVILLE, KY NPI 1477058071

General Payments — all program years on this page

$868.60

  • Category: General Payments
  • Program years: PY2021–2024
  • Record count: 46
  • As of (CMS publication): 2026-01-23

Latest program year (PY2024): $354.10 across 20 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2024) · sorted by reported total.

Nature of paymentAmountRecords
Food and Beverage $305.2619
Education $48.841

By paying entity

Latest program year (PY2024) · sorted by reported total.

By program year

Program yearAmountRecords
2021 $76.005
2022 $171.009
2023 $267.5012
2024 $354.1020

Records — PY2024 (20)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
1096579225 Novo Nordisk Inc $14.54 08/02/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1097611204 Novo Nordisk Inc $15.28 04/03/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1103759276 ABBVIE INC. $27.13 02/08/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104397399 AstraZeneca Pharmaceuticals LP $14.28 11/11/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1118894678 Otsuka America Pharmaceutical, Inc. $25.10 03/14/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1143227007 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $16.96 01/13/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1143227011 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $48.84 01/26/2024 Education Undisputed 01/23/2026 View at CMS
1143227014 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $11.99 01/27/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1143227018 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $13.80 05/07/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1143227022 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $10.21 05/24/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1143227026 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3.86 05/24/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1143227029 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $15.17 06/10/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1143227033 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $20.84 11/08/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1144607755 Xeris Pharmaceuticals, Inc. $15.28 05/08/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1144607757 Xeris Pharmaceuticals, Inc. $17.00 07/31/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1148308560 Axsome Therapeutics, Inc. $16.50 01/25/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1148308562 Axsome Therapeutics, Inc. $16.50 03/08/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1148308564 Axsome Therapeutics, Inc. $14.83 05/03/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1149598612 Smith+Nephew, Inc. $15.42 01/03/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1150856234 Neurocrine Biosciences, Inc. $20.57 06/14/2024 Food and Beverage Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.